The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of empegfilgrastim, a novel pegylated G-CSF: Results of complete analysis after 4 cycles of myelosuppressive chemotherapy in phase III double-dummy randomized clinical study.
 
Olga Filon
No Relationships to Disclose
 
Marina Nechaeva
No Relationships to Disclose
 
Olga Burdaeva
No Relationships to Disclose
 
Vladimir Ivanovich Vladimirov
No Relationships to Disclose
 
Igor Lifirenko
No Relationships to Disclose
 
Nadezhda Vitalievna Kovalenko
No Relationships to Disclose
 
Mikhail V. Kopp
No Relationships to Disclose
 
Marina Matrosova
No Relationships to Disclose
 
Guzel Mukhametsina
No Relationships to Disclose
 
Sergey Panchenko
No Relationships to Disclose
 
Pavel Skopin
No Relationships to Disclose
 
Daniil Stroyakovskiy
No Relationships to Disclose
 
Petr Krivorotko
No Relationships to Disclose
 
Julia Shapovalova
No Relationships to Disclose
 
Irina Jelvakova
No Relationships to Disclose
 
Ludmila Sheveleva
No Relationships to Disclose
 
Anastasia Abrosimova
No Relationships to Disclose
 
Roman Ivanov
No Relationships to Disclose
 
Sergei Tjulandin
Speakers' Bureau - AstraZeneca; Eisai; Pfizer; Sanofi
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Boehringer Ingelheim; Merck Serono